62400-75-3

Usage

Uses

Used in Pharmaceutical Industry:
5-Hydroxymethyl-pyrrolidine-2-one is used as a building block for the synthesis of various pharmaceutical compounds. Its unique structure allows for the creation of new molecules with potential therapeutic properties, contributing to the development of novel drugs.
Used in Cancer Research:
5-Hydroxymethyl-pyrrolidine-2-one is used as an analog of Pramanicin, a compound that induces apoptosis in human colon cancer cells. Its role in cancer research is significant, as it may help in the development of new treatments for colon cancer and other related malignancies.
Used in Stereochemistry:
5-Hydroxymethyl-pyrrolidine-2-one is also available with specified stereochemistry, which is crucial for its application in the synthesis of chiral molecules. The stereochemistry of 5-hydroxymethyl-pyrrolidine-2-one can be tailored to meet specific requirements in the pharmaceutical and chemical industries, enhancing its utility in the development of enantiomerically pure compounds.

Upstream product

• 124-63-0 methanesulfonyl chloride 
• 98-79-3 L-Pyroglutamic acid 
• 1159991-66-8 N-[(mesitylcarbonyl)oxy]pent-4-enamide 
• 66183-71-9 ethyl 2-oxopyrrolidine-5-carboxylate 
• 149-87-1 Pyroglutamic acid 
• 4931-66-2 methyl 5-oxopyrrolidine-2-carboxylate 
• 123-91-1 1,4-dioxane 
• 4931-68-4 (S)-butyl 5-oxopyrrolidine-2-carboxylate 
• 5831-75-4 5-(iodomethyl)-2-pyrrolidinone 
• 100556-54-5 C₁₁H₂₅NOSi₂ 
• 39716-58-0 pent-4-enoyl chloride 
• 6852-94-4 4-pentenamide 
• 591-80-0 pent-4-enoic acid 

Downstream Products

• 82259-09-4 (racemic)-5-(2'-propenyl)-2-pyrrolidinone 
• 130092-20-5 (trans)-4-cyclohexyl-L-proline 
• 70960-97-3 4-fluoromethyl-4-amino-butyric acid 
• 62400-90-2 5‐oxopyrrolidine‐2‐carbaldehyde 
• 838872-71-2 5-hydroxymethyl-1-[4-(methoxymethoxy)phenyl]pyrrolidin-2-one 
• 177911-57-8 5-(((tert-butyldimethylsilyl)oxy)methyl)pyrrolidin-2-one 
• 154148-69-3 5-(aminomethyl)-2-pyrrolidinone 
• 1312454-15-1 (5-oxopyrrolidin-2-yl)methyl benzenesulfonate 
• 1309077-14-2 3-hydroxymethyl-2-azabicyclo[3.1.0]hexane-2-carboxylic acid tert-butyl ester 
• 1309077-13-1 3-(tert-butyldiphenylsilanyloxymethyl)-2-azabicyclo[3.1.0]hexane-2-carboxylic acid tert-butyl ester 
• 157979-35-6 2-(tert-butyldiphenylsilanyloxymethyl)-5-methoxypyrrolidine-1-carboxylic acid tertbutyl ester 
• 157979-33-4 2-(tert-butyldiphenylsilanyloxymethyl)-5-hydroxy pyrrolidine-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF

The present disclosure relates to Fused Morpholinopyrimidines, pharmaceutical compositions comprising an effective amount of a Fused Morpholinopyrimidine and methods for using a Fused Morpholinopyrimidine in the treatment of a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of a Fused Morpholinopyrimidine.

FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF

The present disclosure relates to Fused Morpholinopyrimidines, pharmaceutical compositions comprising an effective amount of a Fused Morpholinopyrimidine and methods for using a Fused Morpholinopyrimidine in the treatment of a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of a Fused Morpholinopyrimidine.

CARBONITRILE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS

The present invention relates to a compound of Formula 1, 2 or 3: I II III wherein A is N or -CR0--, where R0 is hydrogen, C1-C6 linear or branched chain alkyl, etc., Z is -CRe --, or, -N--, where Re is hydrogen, C1 -C6 linear or branched chain alkyl, etc.; R1 is hydrogen, C1 -C6 linear or branched chain alkyl, etc.; R2 are independently hydrogen or C1-C6 linear or branched chain alkyl; R3 and R4 are independently hydrogen, C1C6 linear or branched chain alkyl, etc.;. R5 and R6 are independently hydrogen or C1-C6 linear or branched chain alkyl, etc.; R8 is hydrogen, C1 -C6 linear or branched chain alkyl, etc.; R9 and R10 are independently hydrogen or C1- C6 linear or branched chain alkyl, etc.; Q is --CO--, --(CH2)q--, --(CHRs)q--, or -(CRsRt)q- -, where Rs and Rt are independently C1-C6 linear or branched chain alkyl, aryl, alkylaryl, heteroaryl or alkylheteroaryl; where q is 0, 1, 2, or 3; and, where n is 0, 1, 2, 3, 4 or 5; or, a pharmaceutically acceptable salt thereof, for the treatment of certain diseases, particularly those affected or mediated by the androgen receptor; to compbinations comprising such compounds with a second pharmaceutically active ingredient; to compositions containing such combinations; and to such combinations for the treatment of various diseases, particularly, those affected or mediated by the androgen receptor.

PROCESS FOR STRAIGHTENING KERATIN FIBRES WITH A HEATING MEANS AND DENATURING AGENTS

The invention relates to a process for straightening keratin fibres, comprising: (i) a step in which a straightening composition containing at least two denaturing agents is applied to the keratin fibres, (ii) a step in which the temperature of the keratin fibres is raised, using a heating means, to a temperature of between 110 and 250° C.

Tethered aminohydroxylation (TA) reaction of amides

The first examples of amide-tethered aminohydroxylation reactions, catalyzed by osmium, showing that the use of N-O-based reoxidants are essential for success, are reported. The system that is described is compatible with a variety of different alkene sub

Synthesis of 5-(hydroxymethyl)pyrrolidin-2-ones by cyclization of amide dianions with epibromohydrin

The reaction of amide and thioamide dianions with epibromohydrin resulted in regioselective formation of 5-(hydroxymethyl)pyrrolidin-2-ones (pyroglutaminols) and -thiones. The cyclization of the dianion of N-(2-tert-butylphenyl)acetamide with epibromohydr

Pyrrolidin-2-one compounds and their use as neuraminidase inhibitors

A compound having the formula: wherein all variables are as defined in the specification, for use as a neuramninidase inhibitor.

Synthesis and Reactions of Iodo Lactams

The synthesis of a series of iodo lactams has been achieved by a new cyclization method that depends on generating N,O-bis(trimethylsilyl)imidate derivatives as intermediates.Treatment of an unsaturated amide with trimethylsilyl triflate in pentane and then iodine in tetrahydrofuran gives the iodo lactam.Some reactions of this new difunctional group with bases, nucleophiles, and Michael acceptors leading to functionalized or elaborated lactams are presented.In general, iodo lactams undergo direct SN2 reactions with reactive (but weakly basic) nucleophiles like azide and triphenylphosphine and elimination or decomposition in the presence of bases or basic nucleophiles.Sodium hydride may be used to generate an N-acylaziridine intermediate, which can be opened with azide to deliver an azido lactam with overall retention of stereochemistry.Silver-assisted solvolysis of iodo lactams gives the hydroxy lactams with retention of configuration, probably also because of participation by the lactam nitrogen.The sodium salt of 5-(iodomethyl)-2-pyrrolidinone (3), generated at -20 deg C, undergoes an annulation reaction with unsaturated esters (but not sulfones), leading to pyrrolizidine derivatives.